An interventional study of Disclosing Recovery: A Decision Aid and Toolkit in Opioid Use Disorder, sponsored by University of Delaware. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-18.
Sponsored by University of Delaware · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to test a disclosure intervention among people in treatment for opioid use disorder. The main question it aims to answer is whether people who receive a disclosure intervention have better treatment- and recovery-related outcomes one year after receiving the intervention. Participants will complete a brief disclosure intervention designed to help them (1) make key disclosures related to disclosure and (2) build skills to disclose. Researchers will compare results to participants in a waitlist comparator condition, who receive the intervention at the end of the study.
1,472 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
This study's planned enrollment of 480 is above the median of 63 across 1,166 interventional studies indexed under Opioid-Related Disorders.
Browse Opioid-Related Disorders studies →University of Delaware is the lead sponsor of 128 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants complete a one-hour disclosure intervention for people in treatment for opioid use disorder. The intervention is facilitated by a workbook and accompanying worksheet.
Behavioral: Disclosing Recovery: A Decision Aid and Toolkit
Participants do not complete the disclosure intervention at their baseline appointment. They are given the opportunity to complete the disclosure intervention at their final appointment.
The Disclosing Recovery intervention is designed to help people in treatment for opioid use disorder (1) make key decisions regarding disclosure, including whether, why, what, how, and when to disclose, and (2) build skills to disclose, including planning what to say, practicing disclosure, and preparing for negative responses.
Also known as: Disclosing Recovery
Retention in treatment
Whether participants are retained in treatment 1 year after baseline
Time frame: 1 year
Illicit opioid use
Percentages of drug screens that are positive for illicit opioid use
Time frame: 1 year
Recovery capital score
Average scores on recovery capital measure (titled: Brief Assessment of Recovery Capital); items are measured on a 1-5 point Likert-type scale, and composite scores range from 1-5. Higher values indicate greater recovery capital.
Time frame: 1 year
Quality of life score
Average scores on quality of life measure (titled: European Health Interview Survey-Quality of Life - 8 item); items are measured on a 1-5 point Likert-type scale, and composite scores range from 1-5. Higher scores indicate greater quality of life.
Time frame: 1 year
Plan to share: Yes — De-identified data from this project will be shared via the National Addiction \& HIV Data Archive Program (NAHDAP), which is hosted by the Inter-university Consortium for Political and Social Research (ICPSR). Responses to surveys and medical record data will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be made available no later than when the primary outcome paper is published or when the award ends, whichever comes first. The data will be shared indefinitely.
Access criteria: Data will be accessible through the National Addiction \& HIV Data Archive Program (NAHDAP). NAHDAP will make data available via restricted-use files (which will require a signed Restricted Data Use Agreement between the requestor's institution and the University of Michigan as well as an application to request access). ICPSR/NAHDAP will approve or deny access based on the results of the application review.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.